KRAS and colorectal cancer: This acts on the GTP-bound form of KRAS G12D, and has induced measurable responses in pre-clinical cell line derived mouse models of KRAS G12D mutated NSCLC and PDAC, although less so in colorectal cancer models (Jiang et al., 2023).